semaglutide ckd trial Semaglutides Are Poised to Remake Chronic Kidney Disease Care flow trial semaglutide chronic kidney

Figures 3d and h)

Spermatozoa are susceptible to oxidative stress due to a lack of their own cellular cytoplasmic antioxidants, high DNA susceptibility to oxidative damage, the presence of abundant polyunsaturated fatty acids (PUFAs) in their membrane, and high ROS production during their movements, generated by mitochondrial activity (18, 85, 89, 118)

Semaglutide is a GLP-1 receptor agonist the medication class behind FDA-approved brands like Wegovy (chronic weight management) and Ozempic (type 2 diabetes)

Clinical trials suggest tirzepatide produces greater average weight loss (up to 22.5%) compared to semaglutide (up to 14.9%), though individual responses vary and both medications are considered highly effective